Link Pharma Chem Limited (BOM:524748)
India
· Delayed Price · Currency is INR 27.79
-1.21 (-4.17%)
At close: Mar 9, 2026
Link Pharma Chem Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 272.89 | 254.33 | 298.98 | 387.58 | 535.61 | 348.13 | Upgrade
|
| Revenue | 272.89 | 254.33 | 298.98 | 387.58 | 535.61 | 348.13 | Upgrade
|
| Revenue Growth (YoY) | 1.00% | -14.93% | -22.86% | -27.64% | 53.85% | 36.68% | Upgrade
|
| Cost of Revenue | 116.81 | 128.97 | 172.93 | 221.75 | 372.08 | 189.58 | Upgrade
|
| Gross Profit | 156.08 | 125.37 | 126.05 | 165.83 | 163.53 | 158.54 | Upgrade
|
| Selling, General & Admin | 59.72 | 53.92 | 55.16 | 56.89 | 57.82 | 56.41 | Upgrade
|
| Other Operating Expenses | 81.78 | 70.15 | 77.23 | 77.81 | 70.7 | 70.78 | Upgrade
|
| Operating Expenses | 151.22 | 133.5 | 142.89 | 147.88 | 137.79 | 135.92 | Upgrade
|
| Operating Income | 4.87 | -8.14 | -16.84 | 17.95 | 25.74 | 22.62 | Upgrade
|
| Interest Expense | -5.18 | -7.76 | -8.72 | -7.61 | -4.51 | -4.4 | Upgrade
|
| Interest & Investment Income | 0.62 | 0.62 | 0.64 | 1.13 | 1.18 | 0.21 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 0.04 | - | 0.44 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.47 | 0 | -0 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -0.17 | -15.27 | -24.89 | 11.47 | 22.85 | 18.42 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.59 | 1.25 | 4.94 | -2.61 | 2.19 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.79 | - | 1.18 | -1.64 | Upgrade
|
| Pretax Income | 1.42 | -14.03 | -19.16 | 8.86 | 26.22 | 16.79 | Upgrade
|
| Income Tax Expense | 0.07 | -3.75 | -5.53 | 2.32 | 7.4 | 5.94 | Upgrade
|
| Net Income | 1.35 | -10.27 | -13.63 | 6.54 | 18.82 | 10.85 | Upgrade
|
| Net Income to Common | 1.35 | -10.27 | -13.63 | 6.54 | 18.82 | 10.85 | Upgrade
|
| Net Income Growth | - | - | - | -65.23% | 73.45% | 14.22% | Upgrade
|
| Shares Outstanding (Basic) | 8 | 4 | 4 | 4 | 4 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 8 | 4 | 4 | 4 | 4 | 4 | Upgrade
|
| EPS (Basic) | 0.17 | -2.31 | -3.07 | 1.47 | 4.24 | 2.44 | Upgrade
|
| EPS (Diluted) | 0.17 | -2.31 | -3.07 | 1.47 | 4.24 | 2.44 | Upgrade
|
| EPS Growth | - | - | - | -65.23% | 73.45% | 14.22% | Upgrade
|
| Free Cash Flow | - | 24.29 | -9.78 | -26 | -24.15 | 30.39 | Upgrade
|
| Free Cash Flow Per Share | - | 5.47 | -2.20 | -5.86 | -5.44 | 6.84 | Upgrade
|
| Gross Margin | 57.20% | 49.29% | 42.16% | 42.79% | 30.53% | 45.54% | Upgrade
|
| Operating Margin | 1.78% | -3.20% | -5.63% | 4.63% | 4.81% | 6.50% | Upgrade
|
| Profit Margin | 0.50% | -4.04% | -4.56% | 1.69% | 3.51% | 3.12% | Upgrade
|
| Free Cash Flow Margin | - | 9.55% | -3.27% | -6.71% | -4.51% | 8.73% | Upgrade
|
| EBITDA | 13.61 | 1.29 | -6.5 | 27.18 | 35.02 | 31.36 | Upgrade
|
| EBITDA Margin | 4.99% | 0.51% | -2.17% | 7.01% | 6.54% | 9.01% | Upgrade
|
| D&A For EBITDA | 8.74 | 9.43 | 10.34 | 9.23 | 9.28 | 8.74 | Upgrade
|
| EBIT | 4.87 | -8.14 | -16.84 | 17.95 | 25.74 | 22.62 | Upgrade
|
| EBIT Margin | 1.78% | -3.20% | -5.63% | 4.63% | 4.81% | 6.50% | Upgrade
|
| Effective Tax Rate | 4.99% | - | - | 26.20% | 28.22% | 35.37% | Upgrade
|
| Revenue as Reported | 274.63 | 256.2 | 305.38 | 386.11 | 540.25 | 348.34 | Upgrade
|
| Advertising Expenses | - | - | - | - | 0.09 | 0.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.